TBB通过WNT/β-catenin通路抑制甲状腺滤泡状癌细胞FTC133的增殖与迁移

目的 观察四溴苯三唑(TBB)对甲状腺滤泡状癌细胞系FTC133的CK2α、β-catemn和SURVIVIN的mRNA和蛋白表达的影响,探讨TBB抗甲状腺癌的作用机制.方法 体外培养FTC133细胞,分对照组(DMSO组)和TBB组(终浓度为12.5、25和50 μmol/L),MTT法测定细胞增殖抑制率;划痕实验测定细胞迁移;RT-PCR和Western blot法分别检测FTC133细胞CK2α、β-catenin和SURVIVIN的mRNA和蛋白表达.结果 与对照组比较,TBB呈剂量依赖性抑制FTC133细胞的增殖和迁移.各TBB处理组CK2α mRNA表达水平明显降低(P ＜0.01);TBB组随着浓度的逐渐加大,CK2α、β-catenin和SURVIVIN蛋白表达下降(P＜0.01).结论 TBB在一定浓度范围内抑制甲状腺滤泡状癌细胞系FTC133的增殖和迁移,其机制可能与TBB下调CK2α表达进而抑制WNT/β-catemn信号通路有关.     

shRNA抑制人肺癌细胞A549 SURVIVIN基因表达

目的 构建存活素(SURVIVIN)基因的短发夹RNA(shRNA)表达质粒,为肺癌RNA干扰(RNAi)途径的基因治疗打下基础.方法 设计并合成SURVIVIN短发夹结构模板序列,与穿梭载体重组质粒后转染人肺癌细胞A549,通过RT-PCR法筛选出抑制效果最强的质粒;MTT和Western blot法检测该质粒对细胞增殖和SURVIVOIN表达的影响.结果 构建和筛选出抑制作用最强的质粒;该质粒能明显抑制A549细胞的增殖和SURVIVIN的表达.结论 在RNAi的介导下,SURVIVIN的表达被下调,为肺癌的基因治疗提供实验依据.     

骨髓增生异常综合征的免疫表型和SURVIVIN、P15INK4B、TRF1基因表达

目的探讨骨髓增生异常综合征（MDS）特征性免疫表型,SURVIVIN、P15INK4B、TRF1基因表达程度,及其与临床病情进展的关系。方法抽取50例MDS患者骨髓细胞,用流式细胞学技术检测免疫表型;抽取单个核细胞,用RT-PCR方法检测SURVIVIN、P15INK4B、TRF1基因mRNA表达程度。结果与对照组相比,MDS患者骨髓细胞原始群CD7和CD34表达增多;粒细胞群CD34表达增多,CD13、CD33、CD11b表达下降;单核细胞表达CD117和CD34。与对照组相比,MDS患者骨髓单个核细胞SURVIVIN和TRF1基因mRNA表达增加,P15INK4B基因mR-NA表达下降（P均〈0.05）。从低危组到高危组,SURVIVIN和TRF1基因mRNA表达增加,P15INK4B基因mRNA表达下降（P均〈0.05）。结论 MDS免疫表型有其特征性,SURVIVIN、P15INK4B和TRF1基因表达可能与其发病进展有关。     

Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer.

BACKGROUND: It has been suggested that progression of superficial bladder cancer may be regulated at the molecular level by a typical pattern of expression of genes involved in apoptosis. Recently LIVIN, belonging to the inhibitors of apoptosis (IAP) family, has been found to be expressed in most solid tumors, where its expression is suggested to have prognostic significance. No data are available concerning the significance of LIVIN in the progression of bladder tumors. PATIENTS AND METHODS: In the present paper we used RT-PCR to investigate the expression of LIVIN isoforms alpha and beta, SURVIVIN, BCL-X and BCL-2/BAX expression ratio both in normal and tumoral bladder tissues, and correlated their expression with the emergence of early relapses in a follow-up of 4 years. This study shows that only the alpha isoform of LIVIN, which is not expressed in normal bladder tissue, is expressed in a proportion of tumors with a high risk of relapse. RESULTS: LIVIN was found in 7/30 patients (23%), SURVIVIN in 9/30 (30%), BCL-2/BAX ratio >1 in 16/30 (53%), BCL-2/BAX expression ratio <1 in 14/30 (46.6%) and BCL-X, only in isoform BCL-X(L), in 11/30 (36.6%). When we evaluated the dependence between each gene expression and relapse free time of patients, we found that LIVIN, high BCL-2/BAX ratio and BCL-X(L), but not SURVIVIN, reached statistical significance in order to predict relapses. CONCLUSIONS: Our findings suggest that LIVIN may be involved in the progression of superficial bladder cancer and used as a marker of early recurrence; while the expression of SURVIVIN cannot be used to identify patients with high risk of relapse.     

AIF、HSP70与SURVIVIN在青海地区胃癌中的表达及临床意义

目的：研究青海地区AIF、HSP70及SURVIVIN在胃癌及胃正常黏膜中的表达情况及其在胃癌发生发展中的作用。方法：采用免疫组化二步法检测60例胃癌组织和60例正常胃黏膜组织中AIF、HSP70及SURVIVIN的表达。结果：胃癌组织中AIF、SURVIVIN及HSP70蛋白免疫组化积分均高于正常胃黏膜组织（P〈0.01）;AIF、SURVIVIN及HSP70蛋白表达在不同年龄、不同性别组无统计学差异（P〉0.05）;AIF表达在不同分期、是否转移以及不同肿瘤细胞分化程度无统计学差异（P〉0.05）;Ⅱ期及Ⅲ期患者胃癌组织HSP 70蛋白积分均高于Ⅰ期（P〈0.01）;Ⅲ期患者胃癌组织SUR-VIVIN蛋白积分高于Ⅰ期（P〈0.05）;低分化组胃癌组织HSP70蛋白积分高于高分化组（P〈0.01）;低分化组胃癌组织SURVIVIN蛋白积分与高分化组比较无明显差异（P〉0.05）;无淋巴结转移者HSP70及SURVIVIN蛋白积分均低于伴有淋巴结转移者（P〈0.05）。SURVIVIN与AIF及HSP70蛋白表达间分别呈正相关（r值分别为0.520及0.772）,HSP70与AIF的表达也呈正相关（r=0.568）。结论：联合检测AIF、HSP70及SURVIVIN的表达有助于检测胃癌恶性程度和转移与否。